Anti-VEGF for Diabetic Retinopathy: A ‘Strong Option’

by MedPage Today • 2017/06/01 • 0 Comments

(MedPage Today) -- But barriers still prevent wide clinical implementation

← North America Eyewear Market 2016-2022: Key Players are Essilor, Safilo, Prada, Fielmann, Carl Zeiss & Johnson and Johnson – Research and Markets

The EyeQue Personal Vision Tracker is Now Available on Amazon.com →